Pain and Fatigue in PsA Linked to Reduced Quality of Life, Physical Function, and Work Productivity
Researchers evaluated the frequency and severity of pain and fatigue in patients with psoriatic arthritis receiving tumor necrosis factor inhibitors.
Psoriatic Arthritis
Adalimumab Biosimilar Gets FDA Approval for Rheumatic Diseases
The FDA has approved Hulio® (adalimumab-fkjp; Mylan), a biosimilar to Humira® (adalimumab; AbbVie).
Enthesitis Associated With Worse Disease Activity and Quality of Life in Psoriatic Arthritis
Researchers assessed the effect of clinical enthesitis in patients with psoriatic arthritis.
Increased Risk for Inflammatory Arthritis in Patients With Newly Diagnosed Hidradenitis Suppurativa
Researchers assessed risk for inflammatory arthritis in patients with newly diagnosed hidradenitis suppurativa.
Psoriasis, Psoriatic Arthritis Associated With Inflammatory Bowel Disease and Other Gastrointestinal Illnesses
Researchers evaluated the association of psoriasis and psoriatic arthritis with inflammatory bowel disease and other gastrointestinal illnesses.
Steroid Injections Improve Pain and Functionality Measures in Hand Psoriatic Dactylitis
Researchers assessed the effectiveness of steroid injections vs systemic treatment on dactylitis in patients with psoriatic arthritis.
Upadacitinib Application for Active Psoriatic Arthritis Submitted for Review
AbbVie has submitted an application to the FDA for review of upadacitinib in the treatment of active psoriatic arthritis (PsA) in adults.
Do TNFis Reduce the Risk for Progression to PsA in Patients With Psoriasis?
Researchers evaluated the use of TNFis vs methotrexate in reducing the risk for progression to psoriatic arthritis in patients with psoriasis.
Integrated Analysis Shows Long-Term Safety, Tolerability of Ixekizumab in Psoriasis, PsA, and axSpA
Researchers evaluated the long-term safety and tolerability of ixekizumab in adults with psoriasis, psoriatic arthritis and axial spondyloarthritis.
![There are no uniform guidelines regarding DMARD tapering. EULAR guidelines suggest RA pharmacotherapy should be de-escalated in the following order: glucocorticoids, biologic DMARDs, and, finally, conventional DMARDs, with each treatment stopping completely before de-escalation of the next agent in the sequence.[4] Numerous DMARD dose-tapering protocols have been studied, including immediate discontinuation of treatment. When the goal is to withdraw treatment, the ACR recommends an initial dose-tapering phase to enable better monitoring of patient response and candidacy for discontinuation.[5] The ACR also strongly encourages patient involvement in decisions regarding their individual DMARD tapering protocol.](https://1fxghyessyy2gaob23ygwzph-wpengine.netdna-ssl.com/wp-content/uploads/sites/18/2019/01/syringedrugsts53728911801_1026507-544x306.jpg)
Literature Review of 2019 EULAR Recommendations for PsA Management Indicates Efficacy, Safety of Pharmacologic Treatment
Researchers performed a review of the efficacy and safety of disease-modifying antirheumatic drugs in psoriatic arthritis.
-
Loading...
-
Loading...
Next post in Spondyloarthritis
